It showed that pembrolizumab improved median OS compared to the control arm in the entire population with PD-L1 expression ≥ 10, according to CPS (9.3 versus 6.7 months, HR: 0.69, p = 0.0074) and in patients with ESCC (8.2 versus 7.1 months, HR: 0.78, p: 0.0095), especially in the Asian population. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.